FDA OKs Risankizumab for Crohn's Disease
— Approval marks the third indication for the IL-23 inhibitor in adults
by Zaina Hamza, Staff Writer, MedPage Today June 17, 2022
The FDA has approved risankizumab (Skyrizi), an interleukin (IL)-23 inhibitor, for the treatment of moderately to severely...